NCI-H211 Cells
USD$700.00*
Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 106 cells for adherent lines or 5 × 106 cells for suspension lines (refer to the batch CoA for details).
General information
| Description | NCI-H211 is a human lung carcinoma cell line classified as non-small cell lung cancer (NSCLC). It was derived from an adult patient and is part of the panel of thoracic malignancy models developed through the NCI-Navy Medical Oncology Branch. The cell line demonstrates epithelial morphology and adherent growth behavior in vitro, making it suitable for monolayer culture systems. It is typically maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum and incubated under standard conditions (37°C, 5% CO₂). On a molecular level, NCI-H211 harbors mutations consistent with NSCLC pathogenesis. Specifically, it possesses an activating KRAS mutation, a hallmark of a subset of lung adenocarcinomas that drives oncogenic signaling through the MAPK and PI3K/AKT pathways. This mutation contributes to the cell line's resistance to certain targeted therapies, particularly EGFR inhibitors, while simultaneously rendering it a useful model for studying KRAS-directed therapeutic strategies. Protein-level profiling studies, such as those using reverse-phase protein arrays (RPPA), have identified NCI-H211 among the KRAS-mutant lung cancer models with specific signaling dependencies, aiding in the identification of biomarkers and therapeutic targets. NCI-H211 has been featured in large-scale proteomic and pharmacologic screens and has been used to evaluate drug sensitivities and protein expression patterns. These features make it an effective model for translational research focused on developing treatment approaches for KRAS-driven NSCLC and investigating resistance mechanisms associated with targeted and cytotoxic agents. |
|---|---|
| Organism | Human |
| Tissue | Metastatic |
| Disease | Lung small cell carcinoma |
| Synonyms | H211, H-211, NCIH211 |
Characteristics
| Age | 50 years |
|---|---|
| Gender | Female |
| Ethnicity | Caucasian |
| Growth properties | Aggregates in suspension |
Regulatory Data
| Citation | NCI-H211 (Cytion catalog number 305837) |
|---|---|
| Biosafety level | 1 |
| NCBI_TaxID | 9606 |
| CellosaurusAccession | CVCL_1529 |
Biomolecular Data
| Mutational profile | Mutation: TP53, Simple, p.Arg248Gln (c.743G>A), Unspecified (PubMed=1312696, PubMed=1565469) |
|---|---|
| Karyotype | Iso(3p), t(3;4)(pter-q12), t(3;11)(qter-p25) |
Handling
| Culture Medium | RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a) |
|---|---|
| Supplements | Supplement the medium with 10% FBS |
| Dissociation Reagent | None |
| Seeding density | 0.1 to 1 x 106 cells/ml |
| Fluid renewal | 2 to 3 times per week |
| Freeze medium | As a cryopreservation medium, we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. |
| Thawing and Culturing Cells |
|
| Incubation Atmosphere | 37°C, 5% CO2, humidified atmosphere. |
| Shipping Conditions | Cryopreserved cell lines are shipped on dry ice in validated, insulated packaging with sufficient refrigerant to maintain approximately −78 °C throughout transit. On receipt, inspect the container immediately and transfer vials without delay to appropriate storage. |
| Storage Conditions | For long-term preservation, place vials in vapor-phase liquid nitrogen at about −150 to −196 °C. Storage at −80 °C is acceptable only as a short interim step before transfer to liquid nitrogen. |
Quality Control & Molecular Analysis
| Sterility | Mycoplasma contamination is excluded using both PCR-based assays and luminescence-based mycoplasma detection methods. To ensure there is no bacterial, fungal, or yeast contamination, cell cultures are subjected to daily visual inspections. |
|---|
Certificate of Analysis (CoA)
| Lot Number | Certificate Type | Date | Catalog Number |
|---|---|---|---|
| 305837-060226 | Certificate of Analysis | 05. Mar. 2026 | 305837 |
-
Related products
Related products